The burgeoning role of paclitaxel in advanced pulmonary malignancy

Corey J. Langer, David S. Ettinger

Research output: Contribution to journalArticlepeer-review


Historically, the treatment of advanced non-small cell lung cancer (NSCLC) with cisplatin-based therapy has been a nearly futile effort. Median survival was seldom greater than six months, and fewer than 20% of those with metastatic NSCLC survived more than one year. In addition, toxicity often equaled, if not exceeded, benefit. Over the past five years, however, we have witnessed an explosion of new agents in advanced lung carcinoma. These new agents - in particular the taxanes, gemcitabine, vinorelbine, and topoisomerase I inhibitors - have breathed new life into clinical research. The therapeutic gains, though modest, are real. Paclitaxel, to a large extent, given either alone or in combination with platinols, has led the charge.

Original languageEnglish (US)
Pages (from-to)67-85
Number of pages19
Issue number2
StatePublished - 1998


  • Chemotherapy
  • Metastatic disease
  • NSCLC (Non-small cell lung cancer)
  • Paclitaxel
  • Paclitaxel-carboplatin combination

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'The burgeoning role of paclitaxel in advanced pulmonary malignancy'. Together they form a unique fingerprint.

Cite this